Atomic Ai Launches With $35 Million Series A Financing To Advance Ai-Driven Rna Structure Platform For Treating Undruggable Diseases

Jan 25, 2023•over 2 years ago

Amount Raised

$35 Million

Round Type

series a

San FranciscoArtificial IntelligenceBiotechnology

Investors

Xu VenturesAix VenturesUc Berkeley Professor And Arc Institute Co Founder Patrick HsuCurai Ceo Neal KhoslaDoug MohrGit Hub Ex Ceo Nat FriedmanAme Cloud VenturesNot BoringGreylockFactory Hq8 VcPlayground Global

Description

Atomic AI, a biotechnology company fusing cutting-edge machine learning with state-of-the-art structural biology to unlock RNA drug discovery, launched today with a $35 million Series A round led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, and renowned angel investors including GitHub ex-CEO Nat Friedman, Doug Mohr, Curai CEO Neal Khosla, and UC Berkeley professor and Arc Institute Co-founder Patrick Hsu.

Company Information

Company

Atomic AI

Location

San Francisco, California, United States

About

Since then, Townshend was quick to add, the company has vastly augmented its models and methods with more raw material, much of which it has created itself in its own wet labs. Fortunately the company has raised a $35 million A round, led by Playground Global, with participation from 8VC, Factory HQ, Greylock, NotBoring, AME Cloud Ventures, as well as angels Nat Friedman, Doug Mohr, Neal Khosla, and Patrick Hsu. (The company previously raised a $7 million seed round.) That means Atomic AI is the only one who, publicly at least, has a system that can take a RNA molecule’s raw data in and spit out a reasonably confident estimate of its structure.

Related People

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech